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hypertension, but the cause of hypertension, other than an
excess of body ﬂuid, is not well known. We hypothesized
that the bulbospinal neurons in the rostral ventrolateral
medulla (RVLM) are stimulated by uremic toxins in patients
with chronic renal failure. To investigate whether RVLM neu-
rons are sensitive to uremic toxins, such as uric acid,
indoxyl sulfate, or methylguanidine, we examined changes
in the membrane potentials (MPs) of bulbospinal RVLM
neurons of Wister rats using the whole-cell patch-clamp
technique during superfusion with these toxins. A
brainstem-spinal cord preparation that preserved the sym-
pathetic nervous system was used for the experiments.
During uric acid, indoxyl sulfate, or methylguanidine super-
fusion, almost all the RVLM neurons were depolarized. To
examine the transporters for these toxins on RVLM neurons,
histological examinations were performed. The uric acid-,
indoxyl sulfate-, and methylguanidine-depolarized RVLM
neurons showed the presence of urate transporter 1
(URAT 1), organic anion transporter (OAT)1 or OAT3,
and organic cation transporter (OCT)3, respectively.
Furthermore, the toxin-induced activities of the RVLM neu-
rons were suppressed by the addition of an anti-oxidation
drug (VAS2870, an NAD(P)H oxidase inhibitor), and a histo-
logical examination revealed the presence of NAD(P)H oxi-
dase (nox)2 and nox4 in these RVLM neurons. The present
results show that uric acid, indoxyl sulfate, and methyl-
guanidine directly stimulate bulbospinal RVLM neurons viahttp://dx.doi.org/10.1016/j.neuroscience.2015.07.055
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oxidative stress. These uremic toxins may cause hyperten-
sion by activating RVLM neurons.  2015 The
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INTRODUCTION
The mechanisms responsible for hypertension during
chronic renal failure are not well known. The major
determinants of the blood pressure (BP) are the cardiac
output, blood volume, ﬂuid viscosity, overall vascular
compliance, and peripheral vascular resistance (Mayet
and Hughes, 2003). In patients with chronic renal failure,
while an increase of the body ﬂuid volume is considered to
be one of the major causes of hypertension (Vasavada
and Agarwal, 2003), there are many renal failure patients
with hypertension who do not necessarily show an excess
of body ﬂuid (Odudu and McIntyre, 2012). Wabel et al.
(2008) showed that volume-dependent hypertension
was observed in only 15% of patients with chronic renal
failure. The removal of uremic toxins through dialysis
often improves hypertension (Vasavada and Agarwal,
2003), but the mechanism by which uremic toxins cause
hypertension is obscure.
The rostral ventrolateral medulla (RVLM), which
contains presympathetic neurons, is known to be a
pivotal region that regulates BP (Madden and Sved,
2003). The neurons in the RVLM project to the intermedi-
olateral cell column (IML), where they connect with the
sympathetic preganglionic neurons that regulate the
peripheral sympathetic function and BP (Dembowsky
et al., 1986; Pilowsky and Goodchild, 2002). Therefore,
if uremic toxins activated these neurons, the BP would
increase. Thus, in this study, we examined the direct
eﬀects of uremic toxins (uric acid, indoxyl sulfate, and
methylguanidine) on bulbospinal RVLM neurons.
Some previous reports have discussed the eﬀects of
hyperuricemia on hypertension (Sa´nchez-Lozada et al.,
2008; Nagahama et al., 2015). Hyperuricemia reportedly
up-regulates the renin-angiotensin-system (Corry et al.,
2008), but the mechanism is not well known. Regarding
indoxyl sulfate, Liu et al. (2012) showed that the accumu-













Fig. 1. Brainstem-spinal cord preparation and antidromic action
potentials. (a) Brainstem-spinal cord preparation of a neonatal Wistar
rat. IX, X, XI, and XII are the numbers of the cranial nerves. Electrical
stimulation was applied to the IML at the Th2 level via an electrode.
(b) Antidromic action potential in an RVLM neuron that was evoked by
electrical stimulation () in the IML at the Th2 level.
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activates the renal renin-angiotensin-system. Methyl-
guanidine also is reported to give eﬀects on BP.
Sorrentino and Pinto (1995) showed that intravenous
administration of methylguanidine increased the mean
BP in a dose-dependent manner in rats and suggested
that the rise in the plasma concentration of methylguani-
dine may contribute to the hypertension seen in patients
with chronic renal failure.
To the best of our knowledge, the direct eﬀects of
uremic toxins on bulbospinal RVLM neurons have not
been previously reported. Previous studies have
demonstrated that these uremic toxins enter the target
cells through speciﬁc transporters (Enomoto et al.,
2003; Taki et al., 2006; Endou and Anzai, 2008;
Tachikawa and Hosoya, 2011) and damage the cells by
producing oxidative stress (Ksiazek and Załuska, 2008;
Tumur and Niwa, 2009; Wang et al., 2010; Shimizu
et al., 2013). Therefore, in this study, we examined the
eﬀects of uric acid, indoxyl sulfate and methylguanidine
on the bulbospinal RVLM neurons using brainstem-
spinal cord preparations (Oshima et al., 2008, 2013,
2014); we also conducted histological analysis to check
for the presence of speciﬁc transporters for these uremic
toxins on the RVLM neurons. To conﬁrm the eﬀects of
oxidative stress produced by these toxins, we investi-
gated the eﬀects of VAS2870 (an NAD(P)H oxidase inhi-
bitor) on the RVLM neurons and conducted histological
evaluation to check for the presence of NAD(P)H oxidase
(nox) in the RVLM neurons.EXPERIMENTAL PROCEDURES
General preparations
Experiments were performed using brainstem-spinal cord
preparations collected from 1- to 5-day-old Wistar rats, as
previously described (Oshima et al., 2008, 2013, 2014).
The experiment protocols were approved by the
Institutional Review Board of National Defense Medical
College and were in accordance with the National
Guidelines for the Conduct of Animal Experiments.
Brieﬂy, the animals were placed under deep ether anes-
thesia and the brainstem-spinal cord was isolated at the
Th2 level; the brainstem was then sectioned between
the roots of cranial nerve VI and the lower border of the
trapezoid body (Fig. 1a). The preparations were continu-
ously superfused with a solution containing (in mmol/L)
124 NaCl, 5.0 KCl, 1.2 KH2PO4, 2.4 CaCl2, 1.3 MgCl2,
26 NaHCO3, and 30-glucose and maintained at
25–26 C (artiﬁcial cerebrospinal ﬂuid [aCSF]). The pH
(7.4) and oxygenation were maintained by bubbling 90%
O2-5% N2-5% CO2 through the solution.Patch-clamp electrodes
Electrodes were pulled in one stage from thin-wall
borosilicate ﬁlament capillaries (GC100TF-10, outer
diameter 1.0 mm; Clark Electromed, Reading, UK) with
a vertical puller. The electrodes had a tip diameter of
1.8–2.0 lm and a resistance of 4–6 MX. The electrode
solution for the whole-cell recordings consisted of (inmmol/L): 130 potassium gluconate, 10 HEPES, 10
EGTA, 1 CaCl2, and1 MgCl2, with the pH adjusted to
7.2–7.3 with KOH. The electrode tips were ﬁlled with
0.2% Lucifer Yellow (Sigma, St. Louis, MO, USA).
Recording procedure
A patch-clamp ampliﬁer (AxoPatch, ID; Axon Instruments,
Sunnyvale, CA, USA) was used to record the membrane
potentials (MPs). The RVLM neurons were sought from
the ventral side of the medulla. To conﬁrm that the
recorded RVLM neuron was a bulbospinal neuron, the
existence of antidromic action potentials (APs) in the
RVLM neurons was examined by electrical stimulation
of the IML at the Th2 level with a tungsten electrode
(30-lm tip diameter; Unique Medical, Tokyo, Japan)
(Fig. 1b). The MPs were recorded using the current-
clamp technique (20 pA increments from 100 to 20 pA,
500 ms in duration). All data were recorded and
analyzed using PowerLab (AD Instruments, Colorado
Springs, CO, USA). The membrane resistances (MRs)
of the RVLM neurons were calculated from the current–
voltage curves. During the course of the whole-cell
recordings, neurons were labeled with 0.2% Lucifer
Yellow (lithium salt; Sigma) by either spontaneous
diﬀusion or iontophoresis.
Experimental protocolsProtocol (1). During the recording of the MPs of the
bulbospinal RVLM neurons, the preparations were
superfused with uric acid (0.05–1 mmol/L [Alvarez-Lario
and Macarro´n-Vicente, 2011], Sigma), indoxyl sulfate
(0.01–5 mmol/L [D’Hooge et al., 2003], Sigma), or methyl-
guanidine (0.001–5 mmol/L [Wang et al., 2010], Sigma)
dissolved in aCSF. The duration of each drug superfusion
was 3–10 min. During the superfusion with each drug, we
deﬁned depolarization as an increase of the MP by more
than 2 mV and hyperpolarization as a decrease of the MP
by more than 2 mV. The changes in the MPs were deter-
mined 3–5 min after the start of superfusion with each
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with tetrodotoxin (TTX, 0.5 mmol/L [Oshima et al.,
2014], Sigma) solution for 10 min to block synaptic trans-
missions from other neurons to the recorded bulbospinal
RVLM neurons. Thereafter, the neurons were superfused
with each toxin (uric acid, 0.5 mmol/L; indoxyl sulfate,
1 mmol/L; and methylguanidine, 1 mmol/L) dissolved in
a TTX solution and the MPs were recorded.
Protocol (2). To examine whether the changes in
RVLM neuron activities caused by uric acid, indoxyl
sulfate, or methylguanidine superfusion were transmitted
to the IML neurons, the MPs of the IML neurons were
recorded and the RVLM areas were micro-superfused
(10–30 lL) with each toxin solution (uric acid,
0.5 mmol/L; indoxyl sulfate, 0.5 mmol/L; or
methylguanidine, 0.5 mmol/L) (Fig. 6a). The brain surface
over the RVLM was superfused with each of the toxins.
Protocol (3). To examine whether the eﬀects of these
uremic toxins on RVLM neurons were caused by an
increase in oxidative stress, VAS2870 (40–80 lmol/L
[Sun et al., 2012b], Sigma) was added to each toxin solu-
tion (uric acid, 0.5 mmol/L; indoxyl sulfate, 0.5 mmol/L; or
methylguanidine, 0.5 mmol/L) during the recording of the
MPs of the bulbospinal RVLM neurons.
Immunoﬂuorescence staining
To determine the presence of speciﬁc transporters for
these toxins histologically, immunoﬂuorescence staining
was performed. After the aforementioned experiments,
the preparations were ﬁxed for 1 h at 4 C in 4%
paraformaldehyde in 0.1 m PBS, immersed in 18%
sucrose-PBS overnight, embedded in optimal cutting
temperature compound (Sakura Finetek, Tokyo, Japan),
frozen on dry ice, and cut into 20-lm-thick transverse
sections, followed by immunoﬂuorescence staining. The
images were obtained using a conventional
ﬂuorescence microscope (LSM510; Carl Zeiss Co.,
Oberkochen, Germany).
Immunoﬂuorescence staining protocols
The Lucifer Yellow-stained RVLM neurons that
responded to uric acid, indoxyl sulfate, or
methylguanidine were examined for each toxin’s speciﬁc
transporter. The following primary antibodies (1:400
dilution) were used for immunoﬂuorescence: rabbit anti-
URAT1 (SLC22A12) antibody (Santa Cruz
Biotechnology, Dallas, TX, USA), rabbit anti-organic
anion transporter (OAT)1 (SLC22A6) antibody (Sigma),
rabbit anti-OAT3 (SLC22A8) antibody (Sigma), and
rabbit anti-organic cation transporter (OCT)3 (SLC22A3)
antibody (Sigma). To conﬁrm that the examined area
was a C1 area, the existence of tyrosine hydroxylase
(TH)-positive neurons in the RVLM was also examined
using mouse anti-TH antibody (Sigma). The secondary
antibodies for ﬂuorescence staining (1:1000 dilution)
were Alexa Fluor 546 goat anti-rabbit immunoglobulin G
(IgG) (Molecular Probes/Invitrogen, Eugene, OR, USA)
and Alexa Fluor 633 goat anti-mouse IgG (Molecular
Probes/Invitrogen).To determine whether depolarization of the RVLM
neurons induced by these uremic toxins was induced by
an increase in oxidative stress via nox, the expression
of nox1, nox2, or nox4 was examined in RVLM neurons
after the preparations were superfused with these
toxins. The following primary antibodies were used for
immunoﬂuorescence: goat anti-nox1 antibody (Sigma),
rabbit anti-nox2 antibody (Abcam, Cambridge, CB, UK),
goat anti-nox2 antibody (Abcam), and rabbit anti-nox4
(Santa Cruz Biotechnology, Dallas, TX, USA). The
secondary antibodies used for the immunoﬂuorescence
staining were Alexa Fluor 633 donkey anti-goat IgG and
Alexa Fluor 546 donkey anti-rabbit IgG.
Statistics
The results were expressed as mean ± SEM.
Comparisons of the MPs recorded before and during (or
after) superfusion with the drugs were performed using
the Student’s t-test for paired observations. Statistical
signiﬁcance was set at P< 0.05.
RESULTS
Eﬀects of uremic toxins on bulbospinal RVLM
neurons
To examine the eﬀects of uremic toxins on the bulbospinal
RVLM neurons, we superfused the bulbospinal RVLM
neurons with each uremic toxin.
Uric acid superfusion: Of the 33 recorded bulbospinal
RVLM neurons, 29 showed depolarization and an
increased frequency of action potential (FAP) during uric
acid superfusion (0.05–1 mmol/L) (Fig. 2a, a1, a2, b,
Table 1).
Superfusion of uric acid dissolved in TTX solution. All
the four recorded bulbospinal RVLM neurons showed
depolarization during superfusion of uric acid dissolved
in TTX solution (MP: before: 42.2 ± 0.4 mV; during:
38.4 ± 0.7 mV; P< 0.05) (Fig. 2c).
Indoxyl sulfate superfusion. All the 14 recorded
bulbospinal RVLM neurons showed depolarization
during indoxyl sulfate superfusion (0.01–5 mmol/L)
(Fig. 3a, a1, a2, b, Table 2).
Superfusion of indoxyl sulfate in TTX solution. All the
four recorded bulbospinal RVLM neurons showed
depolarization during superfusion of indoxyl sulfate
dissolved in TTX solution (before: 47.4 ± 1.5 mV;
during: 44.8 ± 1.6 mV; P< 0.05) (Fig. 3c).
Methylguanidine superfusion. Of the 29 recorded
RVLM neurons, 27 showed depolarization during
methylguanidine superfusion (0.001–5 mmol/L) (Fig. 4a,
a1, a2, b, Table 3).
Superfusion of methylguanidine in TTX solution. All
the ﬁve recorded bulbospinal RVLM neurons recorded
showed depolarization during superfusion of
methylguanidine dissolved in TTX solution (before,




























Fig. 2. Bulbospinal RVLM neurons showing depolarization during uric acid superfusion. (a) The neuron was depolarized by a low concentration
(0.05 mmol/L) of uric acid. During uric acid superfusion (0.05 mmol/L), the RVLM neurons (n= 9) were depolarized (a1), and the FAP in the RVLM
neurons increased (a2). White bar, before uric acid superfusion; black bar, during uric acid superfusion; values are mean ± SEM. *P< 0.05,
#P< 0.01 vs. before uric acid superfusion. (b) The neuron was depolarized by a high concentration (1 mmol/L) of uric acid. (c). The neuron was
depolarized during superfusion with uric acid dissolved in TTX solution.
Table 1. Depolarization in bulbospinal RVLM neurons during uric acid superfusion
Concentration (nmol/L) Depolarized/examined MP (mV) FAP (Hz) MR (MX)
0.05 9/9 Before 44.6 ± 0.6 0.3 ± 0.9 322 ± 20
During 40.2 ± 1.1# 1.4 ± 0.3⁄ 281 ± 11
0.1 3/3 Before 44.4 ± 0.3 0.7 ± 0.6 408 ± 8
During 40.7 ± 0.3⁄ 1.8 ± 1.4 376 ± 6
0.5 9/11
(no change, 1; hyperpolarization, 1)
Before 44.7 ± 1.8 0.3 ± 0.2 458 ± 70
During 39.2 ± 1.9# 1.2 ± 0.5⁄ 471 ± 83
1 8/10
(no change, 2)
Before 45.1 ± 1.8 0.3 ± 0.9 543 ± 94
During 40.0 ± 1.3# 1.9 ± 0.5⁄ 535 ± 97
Total 29/33
MP: membrane potential; MR: membrane resistance; FAP: frequency of action potential. Values are mean ± SEM; ⁄P< 0.05, #P< 0.01 vs. before each drug superfusion.
For MP, FAP, and MR, data were obtained from UA-depolarized neurons only.
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(Fig. 4c).
The MRs tended to decrease during exposure to each
uremic toxin. Overall, however, we observed no
statistically signiﬁcant changes in the MRs during
superfusion of the neurons with each of the toxins.Eﬀects of VAS2870 on uremic toxin-depolarized
RVLM neurons
During VAS2870 (40–80 lmol/L) superfusion, eight of the
10 bulbospinal RVLM neurons were hyperpolarized
(before, 42.6 ± 1.0 mV; during, 45.8 ± 1.0 mV;
P< 0.01; FAP: before, 0.8 ± 0.1 Hz; during,
0.1 ± 0.1 Hz; P< 0.05).
To examine the eﬀects of VAS2780 on uremic toxin-
depolarized RVLM neurons, we added VAS2870 to a
solution in which one of the toxins had been dissolved.
In all of the ﬁve cases, the addition of VAS2870
hyperpolarized the uric acid-depolarized RVLM neurons
(before: 41.2 ± 2.9 mV; during: 46.2 ± 3.2 mV;P< 0.05; before: 1.7 ± 0.8 Hz; during: 0.2 ± 0.1 Hz)
(Fig. 5a, a1, a2). The addition of VAS2870
hyperpolarized the uric acid-depolarized neurons in a
concentration-dependent manner. In nine of the 10
neurons, the addition of VAS2870 hyperpolarized the
indoxyl sulfate-depolarized RVLM neurons (before,
40.2 ± 0.7 mV; during, 44.3 ± 0.4 mV; P< 0.01;
before, 0.7 ± 0.2 Hz; during, 0.2 ± 0.1 Hz) (Fig. 5b, b1,
b2). In all of the ﬁve neurons, the addition of VAS2870
hyperpolarized the methylguanidine-depolarized RVLM
neurons (before, 39.8 ± 1.0 mV; during,
44.4 ± 1.7 mV; P< 0.05; before, 1.2 ± 0.3 Hz;
during, 0.1 ± 0.2 Hz; P< 0.05) (Fig. 5c, c1, c2).Micro-superfusion with a uremic toxin solution over
an RVLM area
To examine whether the changes in the activities of the
RVLM neurons by the uremic toxins were transmitted to
the IML neurons, we micro-superfused the RVLM areas
with each toxin solution and observed the changes of
Fig. 3. Bulbospinal RVLM neurons showing depolarization during indoxyl sulfate superfusion. (a) The neuron was depolarized by a low
concentration (0.01 mmol/L) of indoxyl sulfate. During indoxyl sulfate superfusion (0.01 mmol/L), the RVLM neurons (n= 4) were depolarized (a1),
and the FAP in the RVLM neurons increased (a2). White bar, before indoxyl sulfate superfusion; black bar, during indoxyl sulfate superfusion;
values are mean ± SEM. *P< 0.05, #P< 0.01 vs. before indoxyl sulfate superfusion. (b) The neuron was depolarized by a high concentration
(1 mmol/L) of indoxyl sulfate. (c) The neuron was depolarized during superfusion with indoxyl sulfate dissolved in TTX solution.
Table 2. Depolarization in bulbospinal RVLM neurons during indoxyl sulfate superfusion
Concentration (mmol/L) Depolarized/examined MP (mV) FAP (Hz) MR (MX)
0.01 4/4 Before 46.0 ± 2.6 0.2 ± 0.1 346 ± 19
During 41.6 ± 2.4# 0.8 ± 0.2⁄ 319 ± 12
0.1 4/4 Before 43.7 ± 1.9 0.3 ± 0.1 638 ± 14
During 39.5 ± 2.3# 0.9 ± 0.1⁄ 525 ± 33⁄
1 3/3 Before 44.2 ± 2.2 0.3 ± 0.1 422 ± 14
During 40.6 ± 2.8⁄ 0.7 ± 0.2 366 ± 33
5 3/3 Before 44.4 ± 0.2 0.2 ± 0.1 465 ± 62
During 33.2 ± 1.7⁄ 0.8 ± 0.1⁄ 355 ± 55
Total 14/14
MP: membrane potential; MR: membrane resistance; FAP: frequency of action potential. Values are mean ± SEM; *P< 0.05, #P< 0.01 vs. before each drug superfusion.
For MP, FAP, and MR, data were obtained from IS-depolarized neurons only.
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superfusion of the brain surface over the RVLM with a
uric acid solution caused depolarization of the IML
neurons at the Th2 level (Fig. 6b, b1, b2) (before:
45.9 ± 0.8 mV; after: 43.0 ± 1.3 mV; P< 0.05;
before: 0.1 ± 0.1 Hz; after: 0.6 ± 0.1 Hz; P< 0.05). In
all of the three cases, micro-superfusion of the brain
surface over the RVLM with indoxyl sulfate solution
activated the IML neurons at the Th2 level (Fig. 6c, c1,
c2) (before: 41.1 ± 0.4 mV; after: 36.2 ± 0.5 mV;
P< 0.01; before: 0.1 ± 0.1 Hz; after: 0.4 ± 0.1 Hz;
P< 0.05). In all of the ﬁve cases, micro-superfusion of
the brain surface over the RVLM with methylguanidine
solution depolarized the IML neurons at the Th2 level
(Fig. 6d, d1, d2) (before: 48.2 ± 1.8 mV; after:
44.2 ± 1.7 mV; P< 0.01; before: 0.4 ± 0.3 Hz; after:
1.6 ± 0.5 Hz; P< 0.05).Immunoreactivity
To determine the presence of speciﬁc transporters for the
uremic toxins histologically, we performedimmunoﬂuorescence staining. Lucifer Yellow staining
was performed after the whole-cell recordings of the
bulbospinal RVLM neurons were completed (Fig. 7a–d).
Five RVLM neurons that showed depolarization during
uric acid superfusion were examined for URAT1
immunoreactivity, and we conﬁrmed all of them were
conﬁrmed to be located in the RVLM and to show
URAT1 immunoreactivity (Fig. 7a). Two of these ﬁve
neurons also showed immunoreactivity for TH (Fig. 7a).
Eight RVLM neurons that showed depolarization
during indoxyl sulfate superfusion were examined for
OAT1 (n= 4) or OAT3 (n= 4) immunoreactivity. As a
result, all of the four indoxyl sulfate-depolarized neurons
recorded showed immunoreactivity for OAT1, and all of
the four indoxyl sulfate-depolarized neurons recorded
showed immunoreactivity for OAT3 (Fig. 7b, c). Two of
the four OAT1-immunoactive and three of the four
OAT3-immunoactive neurons also showed TH
immunoreactivity (Fig. 7b, c).
Five RVLM neurons that showed depolarization
during methylguanidine superfusion were examined for
































Fig. 4. Bulbospinal RVLM neurons showing depolarization during methylguanidine superfusion. (a) The neuron was depolarized by a low
concentration (0.001 mmol/L) of methylguanidine. During methylguanidine superfusion (0.001 mmol/L), the RVLM neurons (n= 7) were
depolarized (a1), and the FAP in the RVLM neurons increased (a2). White bar, before methylguanidine superfusion; black bar, during
methylguanidine superfusion; values are mean ± SEM. #P< 0.01 vs. before methylguanidine superfusion. (b) The neuron was depolarized by a
high concentration (5 mmol/L) of methylguanidine. (c) The neuron was depolarized during superfusion with methylguanidine dissolved in TTX
solution.
Table 3. Depolarization in bulbospinal RVLM neurons during methylguanidine superfusion
Concentration (mmol/L) Depolarized/examined MP (mV) FAP (Hz) MR (MX)
0.001 6/7 (no change, 1) Before 43.8 ± 0.8 0.1 ± 0.1 465 ± 77
During 41.3 ± 0.8# 0.4 ± 0.1# 350 ± 50
0.01 7/7 Before 44.4 ± 1.4 0.3 ± 0.2 345 ± 20
During 40.0 ± 2.8⁄ 1.0 ± 0.3⁄ 262 ± 37#
0.05 3/3 Before 44.1 ± 0.6 0.3 ± 0.1 579 ± 25
During 40.1 ± 0.7⁄ 1.2 ± 0.2⁄ 495 ± 27
0.1 4/4 Before 42.9 ± 0.5 0.1 ± 0.1 428 ± 49
During 38.3 ± 1.3⁄ 0.5 ± 0.1# 399 ± 66
5 7/8 (no change, 1) Before 45.2 ± 2.0 0.2 ± 0.1 509 ± 64
During 38.6 ± 1.1# 1.7 ± 0.6⁄ 427 ± 37
Total 27/29
MP: membrane potential; MR: membrane resistance; FAP: frequency of action potential. Values are mean ± SEM; *P< 0.05, #P< 0.01 vs. before each drug superfusion.
For MP, FAP, and MR, data were obtained from MG-depolarized neurons only.
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neurons also showed TH immunoreactivity (Fig. 7d).
To determine the presence of nox histologically, we
examined the immunoreactivity for nox1, nox2 and
nox4, and several neurons in the RVLM were found to
exhibit nox2 or nox4 immunoreactivity (examined in
three rats) (Fig. 8a2, a3). In the RVLM area, most nox2-
immunoreactive neurons also showed nox4
immunoreactivity (examined in four rats) (Fig. 8b1–3).
However, nox1-immunoreactive neurons were not
observed (examined in three rats) (Fig. 8a1).
Next, the uric acid-depolarized RVLM neurons that
were hyperpolarized by the addition of VAS2870 were
examined for nox4 immunoreactivity (n= 8), and all of
them exhibited nox4 immunoreactivity. A representative
image of a nox4-positive neuron is shown in Fig. 9a.
The indoxyl sulfate-depolarized RVLM neurons thatwere hyperpolarized by the addition of VAS2870 were
also examined for nox4 immunoreactivity (n= 4), and
all of them exhibited nox4 immunoreactivity (Fig. 9b).
The methylguanidine-depolarized RVLM neurons that
were hyperpolarized by the addition of VAS2870 were
examined for nox4 immunoreactivity (n= 4), and all of
them exhibited nox4 immunoreactivity (Fig. 9c).DISCUSSION
In this study, we examined whether uremic toxins (uric
acid, indoxyl sulfate, and methylguanidine) depolarize
bulbospinal RVLM neurons. The results showed that
each toxin was capable of depolarizing the bulbospinal
RVLM neurons (Figs. 2–4). Furthermore, since the
RVLM neurons showed depolarization during
superfusion with each toxin dissolved in a TTX solution
Fig. 5. Eﬀects of VAS2870 on toxin-depolarized RVLM neurons. (a) The addition of VAS2870 hyperpolarized the uric acid-depolarized RVLM
neurons in a concentration-dependent manner. During VAS2870 superfusion, the uric acid-depolarized RVLM neurons (n= 5) were hyperpolarized
(a1), however, no signiﬁcant changes of the FAP in the RVLM neurons were observed (a2). Black bar, before VAS2870 superfusion; gray bar,
during VAS2870 superfusion; values are mean ± SEM. #P< 0.01 vs. before VAS2870 superfusion. (b) The addition of VAS2870 hyperpolarized
the indoxyl sulfate-depolarized RVLM neuron. During VAS2870 superfusion, the indoxyl sulfate-depolarized RVLM neurons (n= 10) were
hyperpolarized (b1), however, no signiﬁcant changes of the FAP in the RVLM neurons were observed (b2). Black bar, before VAS2870 superfusion;
gray bar, during VAS2870 superfusion; values are mean ± SEM. #P< 0.01 vs. before VAS2870 superfusion. (c) The addition of VAS2870
hyperpolarized the methylguanidine-depolarized RVLM neuron. During VAS2870 superfusion, the methylguanidine-depolarized RVLM neurons
(n= 5) were hyperpolarized (c1), and the FAP in the RVLM neurons decreased (c2). Black bar, before VAS2870 superfusion; gray bar, during
VAS2870 superfusion; values are mean ± SEM. *P< 0.05 vs. before VAS2870 superfusion.
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bulbospinal RVLM neurons themselves. To conﬁrm
whether the increased activities of the RVLM neurons
aﬀected the IML neurons, micro-superfusion with these
toxins was performed on an RVLM area during whole-
cell recordings of an IML neuron at the Th2 level. As a
result, the IML neurons were found to be activated 2–
5 s after the micro-superfusion of these toxins over the
RVLM area (Fig. 6b–d). IML neurons, which are
projected by bulbospinal RVLM neurons, form the ﬁnal
common pathway of the central nervous system that
regulates peripheral sympathetic function and BP
(Cabot, 1990; Oshima et al., 2008). Consequently, acti-
vated IML neurons increase peripheral sympathetic nerve
activity. These results suggest that the administration of
these toxins to RVLM neurons increases the peripheral
sympathetic nerve activity and raises the BP.
Immunoﬂuorescence staining showed the speciﬁc
transporters for each of the toxins on the neurons
(Fig. 7a–d). The results suggested that each uremic
toxin increased the activities of the bulbospinal RVLM
neurons through its speciﬁc transporters.RVLM neurons also include C1-catecholaminergic
neurons (Madden and Sved, 2003; Oshima et al.,
2014). Therefore, we examined the TH immunoreactivity
of each toxin-depolarized RVLM neuron and found that
some of these neurons showed TH immunoreactivity
(Fig. 7a–d), suggesting that catecholaminergic RVLM
neurons have speciﬁc transporters for each toxin.
The mechanism of how uremic toxins activate RVLM
neurons is not well known. However, some studies have
shown that oxidative stress induces cell membrane
depolarization (Koliwad et al., 1996). Sa´nchez-Lozada
et al. (2008) showed that indoxyl sulfate or uric acid
induces oxidative stress in renal proximal tubular and vas-
cular endothelial cells via nox4. Therefore, we examined
the existence of nox in RVLM neurons. VAS2870 is a val-
idated nox inhibitor (Altenho¨fer et al., 2012) and was
added to each uremic toxin solution to examine whether
VAS2870 diminishes the activities of RVLM neurons
induced by each uremic toxin. As the results showed,
VAS2870 suppressed the activities of these neurons,
suggesting the presence of toxin-induced oxidative
stress.
Fig. 6. Micro-superfusion with each toxin solution over the RVLM area depolarized the IML neuron. (a) Brainstem-spinal cord preparation. Micro-
superfusion with each toxin solution was performed over the RVLM area during whole-cell recordings of the IML neuron at the Th2 level. (b) The IML
neuron at the Th2 level was depolarized after uric acid micro-superfusion over the RVLM area. After micro-superperfusion of the brain surface over
the RVLM area with uric acid, the IML neurons (n= 4) were depolarized (b1), and the FAP in the IML neurons increased (b2). White bar, before uric
acid superfusion; black bar, after uric acid superfusion; values are mean ± SEM. *P< 0.05 vs. before uric acid superfusion. (c) The IML neuron at
the Th2 level was depolarized after indoxyl sulfate micro-superfusion over the RVLM area. After micro-superfusion of the brain surface over the
RVLM area with indoxyl sulfate, the IML neurons (n= 3) were depolarized (c1), and the FAP in the IML neurons increased (c2). White bar, before
indoxyl sulfate superfusion; black bar, after indoxyl sulfate superfusion; values are mean ± SEM. *P< 0.05, #P< 0.01 vs. before indoxyl sulfate
superfusion. (d) The IML neuron at the Th2 level was depolarized after methylguanidine micro-superfusion over the RVLM area. After micro-
superfusion of the brain surface over the RVLM area with methylguanidine, the IML neurons (n= 5) were depolarized (d1), and the FAP in the IML
neurons increased (d2). White bar, before methylguanidine superfusion; black bar, after methylguanidine superfusion; values are mean ± SEM.
*P< 0.05, #P< 0.01 vs. before methylguanidine superfusion.
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and nox4 inﬂuence the cardiovascular system (Datla
and Griendling, 2010). Therefore, we examined the pres-
ence of nox1, nox2, and nox4 in RVLM neurons using
immunoﬂuorescence staining and were able to show theexistence of nox2 and nox4 in RVLM neurons (Fig. 8a2,
a3, b). In the RVLM area, the presence of nox2 has been
reported by Rubattu et al. (2013), but the presence of
nox4 was not mentioned. In the present study, the pres-
ence of both nox2 and nox4 in the bulbospinal RVLM
Fig. 7. Histological examination of the bulbospinal RVLM neurons in a transverse section. (a) The uric acid-depolarized bulbospinal RVLM neuron
showed both URAT1 (SLC22A12) and TH immunoreactivities. (a1) URAT1-immunoreactive neurons in the RVLM are indicated in red. The arrow
indicates the recorded bulbospinal RVLM neuron. (a2) The TH-immunoreactive neurons in the RVLM are indicated in white. The arrow indicates the
recorded neuron. (a3) The Lucifer Yellow-stained bulbospinal RVLM neuron is shown in green. This neuron exhibited depolarization during uric acid
superfusion. (a4) Triple-merged image of a1, a2, and a3. (b) The indoxyl sulfate-depolarized bulbospinal RVLM neuron exhibited both OAT1
(SLC22A6) and TH immunoreactivities. (b1) OAT1-immunoreactive neurons. The arrow indicates the recorded neuron. (b2) The TH-
immunoreactive neurons. The arrow indicates the recorded neuron. (b3) The Lucifer Yellow-stained neuron that exhibited depolarization during
indoxyl sulfate superfusion. (b4) Triple-merged image of b1, b2 and b3. (c) The indoxyl sulfate-depolarized bulbospinal RVLM neuron exhibited both
OAT3 (SLC22A8) and TH immunoreactivities. (c1) OAT3-immunoreactive neurons. The arrow indicates the recorded neuron. (c2) The TH-
immunoreactive neurons. The arrow indicates the recorded neuron. (c3) The Lucifer Yellow-stained neuron that showed depolarization during
indoxyl sulfate superfusion. (c4) Triple-merged image of c1, c2, and c3. (d) The methylguanidine-depolarized bulbospinal RVLM neuron exhibited
both OCT3 (SLC22A3) and TH immunoreactivities. (d1) OCT3-immunoreactive neurons. The arrow indicates the recorded neuron. (d2) The TH-
immunoreactive neurons. The arrow indicates the recorded neuron. (d3) The Lucifer Yellow-stained neuron that showed depolarization during
methylguanidine superfusion. (d4) Triple-merged image of d1, d2, and d3.
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neurons also demonstrated immunoreactivity for nox2
(Fig. 8b). Furthermore, since uric acid, indoxyl sulfate,
or methylguanidine-depolarized RVLM neurons showed
nox4 expression, each toxin may stimulate RVLM neu-
rons by increasing oxidative stress via nox2 and/or nox4
(Fig. 8a2, a3, b, 9a–c).
Eﬀects of uric acid on bulbospinal RVLM neurons
In the renal proximal tubular cells, uric acid enters the
cells via URAT1 (Endou and Anzai, 2008). In the present
study, all the examined bulbospinal RVLM neurons, which
were depolarized during uric acid superfusion, showed
immunoreactivity for URAT1 (Fig. 7a). These results sug-
gest that uric acid increases BP by activating RVLM neu-
rons through URAT1 on RVLM neurons.Bowman et al. (2010) showed that the level of uric
acid in CSF is approximately one-tenth of the level of uric
acid in plasma. A level of 0.05 mmol/L of uric acid (Fig. 2a,
a1, a2, Table 1) in CSF corresponds to a level of
0.5 mmol/L (8.4 mg/dl) of uric acid in plasma, and such
levels can be present in patients with hyperuricemia.Eﬀects of indoxyl sulfate on bulbospinal RVLM
neurons
Since the speciﬁc transporters for IS are OAT1 and OAT3
(Enomoto et al., 2003; Taki et al., 2006), we examined the
presence of these transporters on RVLM neurons. In the
present study, all the indoxyl sulfate-depolarized RVLM
neurons showed immunoreactivity for OAT1 or OAT3
(Fig. 7b, c). These results suggest that indoxyl sulfate
Fig. 8. Immunoreactivity for nox1, nox2, or nox4 in the RVLM. (a) Nox1, 2, and 4-immunoreactive neurons in the RVLM visualized under high
magniﬁcation. In the RVLM, the presence of nox2 (a2) and nox4 (a3) was observed, whereas nox1 (a1) was not detected. Panels a1 and a3 were
obtained from the same section. (b) In the RVLM, most nox2 immunoreactive neurons also exhibited nox4 immunoreactivity. (b1) Nox2-
immunoreactive neurons in the RVLM. (b2) Nox4-immunoreactive neurons in the RVLM. (b3) Merged image of b1and b2.
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and/or OAT3 expressed on these neurons.
The blood concentration level of indoxyl sulfate in
patients under hemodialysis therapy is 0.2–0.9 mmol/L
(Mozar et al., 2012). Although the level of indoxyl sulfate
in CSF is not well known, Mu¨ting (1965) showed that the
level of indoxyl sulfate in CSF under normal conditions is
3.4 times lower than that in plasma. Furthermore, Ohtsuki
et al. (2002) suggested that the inhibition of brain-to-blood
transport for indoxyl sulfate would occur in uremia, lead-
ing to the accumulation of indoxyl sulfate in the brain.
Therefore, we considered that a level of 0.01 mmol/L of
indoxyl sulfate (Fig. 3a, a1, a2, Table 2) in CSF might
be feasible in patients with uremia.Eﬀects of methylguanidine on bulbospinal RVLM
neurons
Tachikawa and Hosoya (2011) showed that methylguani-
dine is a substrate for OCT3, and Gasser et al. (2009)
indicated the existence of OCT3 in the brain. In this study,
all methylguanidine-depolarized RVLM neurons exhibited
immunoreactivity for OCT3 (Fig. 7d). Methylguanidine
was thought to increase the activities of RVLM neurons
through OCT3 on these neurons.
Methylguanidine is produced from creatinine by
reacting with a hydroxyradical (Yokozawa et al., 1997),
and methylguanidine increased oxidative stress by pro-
ducing H2O2 (Marzocco et al., 2010). However, the rela-
tion between methylguanidine and nox is unknown. In
this study, VAS2870 solution decreased the MPs of
methylguanidine-depolarized RVLM neurons to the level
of the resting MPs of those neurons (Fig. 5c, c1), andmethylguanidine-depolarized neurons exhibited nox4
(Fig. 9c). These results suggest that depolarization in
RVLM neurons during methylguanidine superfusion is
caused by oxidative stress produced via nox2 and/or
nox4 (Fig. 8b).
Eloot et al. (2005) indicated that the plasma methyl-
guanidine concentration in patients with chronic renal fail-
ure was 0.02–0.04 mmol/L. The methylguanidine
concentration in the CSF of patients with uremia is not
well known; however, De Deyn et al. (2001) reported that
the highest methylguanidine concentration in CSF from
their uremic patients was 0.001 mmol/L. In the present
study, since the depolarizing eﬀects of methylguanidine
on RVLM neurons were observed even at a level of
0.001 mmol/L (Fig. 4a, a1, a2, Table 3), we thought that
methylguanidine might participate in increasing the BP
by stimulating RVLM neurons in patients with chronic
renal failure.Other possible causes of increase in the activities of
the RVLM neurons
Rossi et al. (2014) showed that the serum levels of uremic
toxins were independently associated with the serum
levels of interleukin-6 (IL-6), tumor necrosis factor-a
(TNF-a) and interferon gamma (IFN-c) in patients with
chronic kidney disease. Wu et al. (2012) showed that
the cytokines IL-1b, IL-6, and TNF-a, accompanied by
lipopolysaccharide-induced systemic inﬂammation, acti-
vate the microglia in the RVLM to induce neuroinﬂamma-
tion, which leads to an increase in the level of oxidative
stress, which in turn, mediates neurogenic hypertension.
Therefore, in patients with chronic renal failure, uremic
Fig. 9. Histological examination of the bulbospinal RVLM neurons in a transverse section. (a) The uric acid-depolarized RVLM neurons that were
hyperpolarized by the addition of VAS2870 exhibited nox4 immunoreactivity. (a1) Nox4-immunoreactive neurons in the RVLM are indicated in red.
The arrow indicates the recorded bulbospinal RVLM neuron. (a2) The Lucifer Yellow-stained bulbospinal RVLM neuron that showed depolarization
during uric acid superfusion and hyperpolarization after the addition of VAS2870. (a3) Merged image of a1and a2. (b) The indoxyl sulfate-
depolarized RVLM neurons that were hyperpolarized by the addition of VAS2870 exhibited nox4 immunoreactivity. (b1) Nox4-immunoreactive
neurons. The arrow indicates the recorded neuron. (b2) The Lucifer Yellow-stained neuron that showed depolarization during indoxyl sulfate
superfusion and hyperpolarization after the addition of VAS2870. (b3) Merged image of b1 and b2. (c) The methylguanidine-depolarized RVLM
neurons that were hyperpolarized by the addition of VAS2870 exhibited nox4 immunoreactivity. (c1) Nox4-immunoreactive neurons. The arrow
indicates the recorded neuron. (c2) The Lucifer Yellow-stained neuron that showed depolarization during methylguanidine superfusion and
hyperpolarization after the addition of VAS2870. (c3) Merged image of c1 and c2.
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neurons via induction of cytokines. However, in this study,
we used the brainstem-spinal cord preparations of new-
born rats in which systemic inﬂammation cannot be exam-
ined, but we observed depolarization of the bulbospinal
RVLM neurons immediately after superfusion of each of
the toxins. Therefore, we believe that uremic toxins can
have direct eﬀects on the RVLM neurons through their
speciﬁc transporters.CONCLUSIONS
Uremic toxins (uric acid, indoxyl sulfate, and
methylguanidine) increased the activities of bulbospinal
RVLM neurons, and the presence of transporters of
URAT1, OAT1, or OAT3, and OCT3 in the bulbospinal
RVLM neurons was demonstrated histologically. The
toxin-induced activities of RVLM neurons were
abolished by VAS2870 (a nox inhibitor), and thepresence of nox2 and nox4 was conﬁrmed histologically.
Based on these results, uremic toxins may increase the
sympathetic nervous activity in patients with chronic
renal failure, causing hypertension by stimulating RVLM
neurons directly via the production of oxidative stress in
these neurons.DISCLOSURES
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